NCT03910569 The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study
| NCT ID | NCT03910569 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cedars-Sinai Medical Center |
| Condition | Takotsubo Cardiomyopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2019-02-01 |
| Primary Completion | 2029-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2019-02-01 with a primary completion date of 2029-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.
Eligibility Criteria
Inclusion Criteria: * Have received a diagnosis of Takotsubo from their physician and consent to enroll * Submit full medical records needed for Takotsubo adjudication Exclusion Criteria: * Younger than 18 years * Unable to provide informed consent * Unable to provide the necessary documentation needed for screening purposes
Contact & Investigator
C. Noel Bairey Merz, MD, FACC
STUDY DIRECTOR
Cedars-Sinai Medical Center
Frequently Asked Questions
Who can join the NCT03910569 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Takotsubo Cardiomyopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03910569 currently recruiting?
Yes, NCT03910569 is actively recruiting participants. Contact the research team at takotsuboresearch@cshs.org for enrollment information.
Where is the NCT03910569 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT03910569 clinical trial?
NCT03910569 is sponsored by Cedars-Sinai Medical Center. The principal investigator is C. Noel Bairey Merz, MD, FACC at Cedars-Sinai Medical Center. The trial plans to enroll 1,000 participants.